Tandem Diabetes Care, Inc. 2020 Senior Management Cash Bonus Plan

The Tandem Diabetes Care, Inc. 2020 Sr. Management Cash Bonus Plan (the “Bonus Plan”) has been designed to align plan participants with the business goals and strategies of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and to further the objectives of the Company’s executive compensation program. This Bonus Plan is an important part of the Company’s commitment to recognizing key employees who contribute to the achievement of important Company performance goals. Specifically, the objectives of the Bonus Plan are as follows:

The Bonus Plan is primarily intended to reward plan participants for their individual contributions to the Company’s achievement with respect to Company performance objectives for the 2020 fiscal year. However, the Company’s Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”) also has the discretion to consider individual or Company performance after December 31, 2020 and until the date of any actual bonus determination under the Bonus Plan in measuring performance and determining the amount of an award, if any, under the Bonus Plan.

Employees of the Company eligible for an award under this Bonus Plan will be limited to individuals serving as a Vice President or more senior management role within the Company, as determined by the Board of Directors or the Compensation Committee. If, following January 1, 2020, an individual is promoted or hired and becomes an eligible participant under the Bonus Plan at any time during the 2020 calendar year, then the individual will be eligible to participate under the Bonus Plan on a pro-rata basis, calculated in the reasonable discretion of the Compensation Committee, unless otherwise specifically provided by the Board of Directors or the Compensation Committee.

A target cash incentive amount (a “Target Bonus Amount”) for each eligible plan participant will be set as a percentage of the participant’s base salary. Cash incentives may be earned under the Bonus Plan based on the achievement of financial performance objectives, product development milestones, and customer-related objectives. The financial performance objectives are comprised of two parts and will collectively represent 80% of the overall Target Bonus Amount. The product development milestones and customer-related objectives will each represent 10% of the overall Target Bonus Amount, which together with the financial performance objectives, represent 100% of the overall Target Bonus Amount.

The portion of the cash bonuses that relates to our product development milestones generally requires that we submit certain products under development for regulatory clearance and the manufacturing readiness of those products. Subject to the Committee’s final discretion, an individual product development milestone must be achieved within a required time period for the applicable portion of the Bonus Plan to be achieved. Overall goal achievement of our product development milestones will be based on the portion of the product development milestones that we actually achieve during 2020.

The portion of the cash bonuses that relates to the Company key customer-related objectives generally requires the Company to achieve a minimum annual metric related to customer support and services, and achieve a minimum annual percentage of current domestic customers eligible for insurance reimbursement to purchase a new insulin pump. Overall goal achievement is subject to the Compensation Committee’s final discretion, and determination of the Company’s customer related objectives will be based on the level of achievement by the Company during fiscal year 2020.

Bonus payments under the Bonus Plan, if any, will be made at the discretion of the Board or the Committee. The financial performance components and product development components of the Bonus Plan may be earned independent of one another. If the Company does not achieve any portion of any of the financial performance components or the product development components of the Bonus Plan, no payouts will be made unless the Board or the Committee, in their sole discretion, determines that there are other factors that merit consideration in the determination of bonus awards, which may be determined on an individual basis. All determinations and decisions made by the Compensation Committee and the Board of Directors pursuant to the provisions of the Bonus Plan shall be final, conclusive and binding on all persons, and shall be given the maximum deference permitted by law.

Payment of bonuses will be made as soon as practical after the end of the plan year, but not later than March 15, 2021. Participants must be actively employed at the time of payout to be eligible for any bonus payment. The Board of Directors or the Compensation Committee may approve payments to any eligible plan participant. The Board of Directors or the Compensation Committee can modify the Bonus Plan, including timing and form of payments, at any time in their sole discretion. Amounts payable under the Bonus Plan are intended to comply with the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations and thus be exempt from the provisions of Section 409A of the Internal Revenue Code of 1986, as amended. The Board of Directors and the Compensation Committee intend to administer the Bonus Plan in a manner consistent with this rule. Any amounts paid hereunder shall be subject to recoupment in accordance with The Dodd-Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company or as is otherwise required by applicable law.